多模式运动干预对阿尔茨海默病的BDNF和细胞因子水平,认知功能和运动功能的益处:初步研究
Emmanuel Dias de Sousa Lopes1, Flávia Gomes de Melo Coelho1, Sheilla Tribess1
1Center of Research in Physical Activity and Health, Federal University of Triângulo Mineiro, Uberaba 38061-500, Minas Gerais, Brazil.
概括
在阿尔茨海默氏病 (AD) 的老年人中,一项为期12周的多种运动计划改善了认知和运动功能. 该计划还对来自大脑的神经营养因子 (BDNF) 和炎症标志物产生了积极影响.
科学领域:
- 老年学
- 神经科学
- 运动科学
背景情况:
- 身体活动可以增强老年人的运动和认知功能.
- 运动可以调节神经营养和炎症因素.
- 阿尔茨海默病 (AD) 与认知能力下降和运动障碍有关.
研究的目的:
- 对阿尔茨海默病老年人的认知功能进行12周多种运动计划的研究.
- 评估该计划对机动性能的影响.
- 检查来自大脑的神经营养因子 (BDNF) 和细胞因子的血水平的变化.
主要方法:
- 这是一项非随机对照试验,共有23名被诊断患有轻度至中度阿尔茨海默病的参与者 (62-85岁).
- 干预组 (n=7) 每周进行60分钟的多模式运动.
- 对照组 (n=8) 保持正常活动;用于基线比较的对照组是认知健康的.
主要成果:
- 干预组的执行和注意力功能 (FAB,CDT) 显著改善.
- 观察到增加了运动能力,平衡,步行速度和下肢力量.
- 血BDNF水平升高和IL-2水平降低.
结论:
- 多种运动对患有阿尔茨海默症的老年人有认知和运动上的好处.
- 该计划对与神经可塑性和炎症相关的生物标志物进行了积极调节.
- 运动可以作为阿尔茨海默病管理的宝贵补充措施.
相关概念视频
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666